1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU Pharma Reform, SPCs, Compulsory Licensing Among Parliament’s ‘Unfinished Business’

 
• By Ian Schofield

A number of legislative proposals will be coming under scrutiny at the newly constituted European Parliament in the coming months, including the pharma reform package and draft legislation on EU-level compulsory licensing and “unitary” supplementary protection certificates.

bundles bales of paper documents. stacks packs pile on the desk in the office
The European Parliament has identified 174 ongoing legislative dossiers • Source: Shutterstock

On 23 July, each of the new European Parliament’s 20 standing committees will hold a “constitutive” meeting during which they will elect a chair and up to four vice-chairs in preparation for the new legislative session.

They include the committee on the environment, public health and food safety (ENVI) and the legal affairs committee (JURI), which together will be responsible for steering the parliament’s discussions on the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.